NASDAQ · SLN
Healthcare · Biotechnology
$9.65
Down-$0.21 (-2.13%)
Updated Oct 13, 2026, 1:05 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SLN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
SLN closed at $9.65 after 21 trading sessions, down 26.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $9.70 | $10.355 | $9.58 | $9.65 | 550.99K |
| Oct 9, 2026 | $9.45 | $10.39 | $9.45 | $9.86 | 844.35K |
| Oct 8, 2026 | $9.71 | $9.72 | $9.055 | $9.52 | 1.11M |
| Oct 7, 2026 | $9.77 | $10.14 | $9.60 | $9.82 | 1.32M |
| Oct 6, 2026 | $10.12 | $10.185 | $9.63 | $9.83 | 1.58M |
| Oct 5, 2026 | $10.62 | $10.65 | $10.0527 | $10.14 | 976.3K |
| Oct 2, 2026 | $10.77 | $10.78 | $10.38 | $10.64 | 973.33K |
| Oct 1, 2026 | $10.98 | $11.05 | $10.49 | $10.71 | 1.58M |
| Sep 30, 2026 | $10.85 | $11.30 | $10.65 | $10.93 | 1.36M |
| Sep 29, 2026 | $11.19 | $11.255 | $10.76 | $10.80 | 884.61K |
| Sep 28, 2026 | $11.13 | $11.415 | $11.01 | $11.20 | 710.71K |
| Sep 25, 2026 | $11.25 | $11.4699 | $11.025 | $11.18 | 953.24K |
| Sep 24, 2026 | $11.50 | $11.70 | $11.175 | $11.22 | 691.39K |
| Sep 23, 2026 | $12.21 | $12.35 | $11.06 | $11.51 | 876.99K |
| Sep 22, 2026 | $12.27 | $12.50 | $12.1705 | $12.29 | 382.05K |
| Sep 21, 2026 | $12.39 | $12.44 | $12.03 | $12.25 | 665.75K |
| Sep 18, 2026 | $12.59 | $12.74 | $12.14 | $12.20 | 1.14M |
| Sep 17, 2026 | $12.76 | $13.00 | $12.57 | $12.70 | 690.47K |
| Sep 16, 2026 | $12.53 | $12.775 | $12.241 | $12.50 | 983.81K |
| Sep 15, 2026 | $13.11 | $13.11 | $12.10 | $12.46 | 1.38M |
| Sep 14, 2026 | $12.95 | $13.28 | $12.72 | $13.06 | 1.1M |
The latest Smart Investors Daily articles mentioning SLN.
Company
Market Activity
Research & News
SLN research
Company profile and research snapshot.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Sep 16, 2026
Silence Therapeutics plc (SLN) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 8:30 AM EDTCompany ParticipantsSteven Romano -...
Yahoo · Sep 2, 2026
LONDON, September 02, 2026--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast.
Benzinga · Aug 11, 2026
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.
SeekingAlpha · Aug 11, 2026
2026-08-11. The following slide deck was published by Silence Therapeutics plc in conjunction with this event.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLN.
